NCT03275857 is a EARLY_PHASE1 clinical trial of Cisplatin in Prostate Cancer, sponsored by University of Rochester.

Who is sponsoring NCT03275857?

NCT03275857 is sponsored by University of Rochester.

What drugs are being tested in NCT03275857?

Interventions in NCT03275857: Cisplatin.

What condition does NCT03275857 study?

NCT03275857 studies Prostate Cancer.

Is NCT03275857 still recruiting?

NCT03275857 is currently completed. Last updated 10 June 2024.

Last reviewed 2024-06-10 · How we verify

NCT03275857

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cisplatin in Castration Resistant Prostate Cancer

Completed EARLY_PHASE1 Last updated 10 June 2024

What this trial tests

EARLY_PHASE1 trial testing Cisplatin in Prostate Cancer in 12 participants. Completed in 31 July 2023.

Timeline

21 September 2018

Primary endpoint
31 July 2023

31 July 2023

Quick facts

Lead sponsor	University of Rochester
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	21 September 2018
Primary completion	31 July 2023
Estimated completion	31 July 2023
Sites	1 location across United States

Drugs / interventions tested

Cisplatin (cisplatin) — full drug profile →

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

University of Rochester

Who can join

18 and older, any sex, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is hypothesized that treatment with cisplatin will reverse emerging refractoriness to enzalutimide in patients with CRPC by affecting AR function.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

ML216-Induced BLM Helicase Inhibition Sensitizes PCa Cells to the DNA-Crosslinking Agent Cisplatin.
Ma XY, Zhao JF, Ruan Y, Zhang WM, et al · · 2022 · cited 4× · PMID 36557923 · DOI 10.3390/molecules27248790
Synergistic effects of bloom helicase (BLM) inhibitor AO/854 with cisplatin in prostate cancer.
Ma X, Tian F, Xiao Y, Huang M, et al · · 2024 · cited 1× · PMID 39438537 · DOI 10.1038/s41598-024-75938-5
Acquired resistance to irradiation or docetaxel is not associated with cross-resistance to cisplatin in prostate cancer cell lines.
Donix L, Erb HHH, Peitzsch C, Dubrovska A, et al · · 2022 · cited 1× · PMID 35020044 · DOI 10.1007/s00432-022-03914-5
Ferroptosis and prostate cancer: A translational path from molecular mechanisms to precision therapy.
Huang Y, Ma Y, He J, Song T. · · 2026 · PMID 42233093 · DOI 10.1016/j.gendis.2025.101967
Linking Iron Metabolism, Ferroptosis, and Cancer: New Targets and Prospects for Effective Anticancer Therapeutic Interventions.
Kourti M, Kontoghiorghes GJ. · · 2026 · PMID 42122232 · DOI 10.3390/cancers18091436

Verify or expand the search:

Other trials of Cisplatin

Trials testing the same drug.

NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
NCT07195734 — Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer · Phase 2 · recruiting
NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT06724042 — Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors · Phase 1 · not yet recruiting

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other University of Rochester trials

Trials by the same sponsor.

NCT07075965 — Calcium Channel Blocker in Myotonic Dystrophy Type 1 · Phase 1 · not yet recruiting
NCT07423104 — A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloi · Phase 2 · not yet recruiting
NCT05744869 — SBAT for Health Equity · NA · not yet recruiting
NCT06052956 — Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses · Phase 2 · not yet recruiting
NCT07032636 — Reducing Crises and Suicide Within the Idaho Army National Guard · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03275857 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Rochester
Last refreshed: 10 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03275857.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing